AzTrials
AzTrials

MumpsPhase 3MIPSNCT05894395

Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination

A Phase 3 study testing MMR booster vaccination (as M-M-R-VaxPro) in people with Mumps and Measles, run by University of Zurich at 2 sites in Switzerland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to investigate the immunity of persons fully vaccinated against measles, mumps and rubella and to examine the course of immunity after booster vaccination. Read more about this study

Who is it for?
Ages 18 to 49 yearsHealthy volunteers can take part
Conditions the study is for
Mumps, Measles, Rubella
What is being tested?
MMR booster vaccination (as M-M-R-VaxPro)
Type of treatment
Vaccines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
2 sitesSwitzerland
Study dates
1 Dec 2023to 1 Sep 2025
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 49 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Aged 18-49 (inclusive) at the time of the study screening visit
  • Has received exactly two previous doses of MMR-containing vaccine at any point up to one calendar year prior to the study screening visit
  • Willing to receive a booster MMR vaccination as outlined in the study protocol
  • Able and willing to comply with all other study requirements (attend all study visits and provide blood, saliva, nasal wash samples at each visit as outlined)
  • Sufficient language (German or English) and cognitive skills
  • Provides written, informed consent to participate in the study

Who cannot join

  • Acute respiratory or other infections (postpone baseline visit until resolved)
  • Receipt of any other vaccination less than 4 weeks prior to the baseline visit or intention to receive another vaccination within 4 weeks following the baseline visit
  • Previous hypersensitivity reaction following receipt of any MMR-containing vaccine or previous hypersensitivity reaction to any component of M-M-R-vaxPro
  • Pregnancy, lactation, or intention to become pregnant during the study
  • Individuals with confirmed or suspected immunosuppressive or immune-deficient state
  • Known current or chronic or severe disease
Show all 9Show fewer
  • Receipt of blood or plasma transfusions, or administration of immune globulin (IG) less than 12 weeks prior to the baseline visit, or intention to receive IG within 4 weeks following the baseline visit
  • Any other significant disease, disorder, or finding which could potentially result in an increased risk to the volunteer due to participation in the study
  • Being enrolled in another interventional study that may interfere with the current study

Trial locations and contacts

2 sites in 1 country.

Phung Lang, Ph.D. contact

+41 44 634 46 72

phung.lang@uzh.ch

Switzerland2 sites, 2 recruiting
  • Epidemiology, Biostatistics and Prevention Institute University of Zurich

    Zurich, 8001

    Kyra Zens, Dr., +41 44 634 46 72, zens@immunology.uzh.ch

    Jan Fehr, M.D.

    Recruiting
  • Epidemiology, Biostatistics and Prevention Institute University of Zurich

    Zurich, 8001

    Phung Lang, PhD, +41 44 634 4672, phung.lang@uzh.ch

    Nora Baer, BA, +41 44 634 4613, mmrstudie@uzh.ch

    Recruiting

Other trials in Switzerland

About this study

Official title: A Cross-Sectional and Open Pre-Post Interventional Study Evaluating Circulating and Mucosal Humoral and Cell-Mediated Immunity Following Measles, Mumps and Rubella (MMR) Vaccination in Adults

The purpose of this study is to investigate the immunity of persons fully vaccinated against measles, mumps and rubella and to examine the course of immunity after booster vaccination.

Read the detailed description

Determining whether individuals respond to vaccination is an important healthcare question with significant public health impact. In recent years there have been surges in cases of measles and mumps; vaccine-preventable diseases which have previously been well-controlled since the introduction of regular vaccination (as MMR) in the 1970s-80s. Since 2016, approximately 10,000-15,000 cases each of measles and mumps have been reported annually in Europe. Despite high vaccination coverage and being declared "measles endemic free", multiple outbreaks have occurred in Switzerland, affecting predominately older adults and young children. While rubella cases remain relatively uncommon, infection during pregnancy can result in Congenital Rubella Syndrome and lead to severe birth defects, underscoring the importance of adequate prevention. All three viruses are highly contagious and transmitted through the oral/respiratory mucosal tissue by contact with infected respiratory secretions.

Importantly, in recent years approximately 30% of measles cases and up to half of mumps cases have been found to occur in individuals receiving at least 2 previous MMR doses, suggesting waning immunity. Although seroconversion after two doses of mumps vaccine (as MMR) nears 90-100%, field effectiveness is closer to 88% (range 75-95%). Booster immunization, however, is not currently indicated in adults. Furthermore, while serum virus-neutralizing antibodies are evaluated as an indicator of responsiveness following mumps vaccination, they are not the correlate of protective immunity. There is need to better understand both 1) The duration of vaccine-elicited protection to all three viruses; and 2) The underlying protective immune mechanisms elicited by vaccination.

Assessments of vaccine responses most often utilize blood to evaluate the establishment of circulating immunity, typically antibodies, in individuals. While antibody responses may predict response to vaccination they may or may not be the immune subset actually responsible for protection. Furthermore, circulating immune responses detectable in the blood are not necessarily representative of responses occurring at mucosal sites. Samples such as saliva, sputum or nasal washes, in contrast, can be collected with relative ease, and can provide insights into the oral and respiratory mucosal environments, which are primary sites of pathogen exposure. Understanding whether specific vaccines elicit immune responses at mucosal sites, that are detectable using minimally-invasive techniques, that correlate with protection from disease, or that can act as a surrogate for circulating responses, would be highly valuable in immune monitoring.

With this study the investigators plan to evaluate persisting measles, mumps and rubella seropositivity in previously-vaccinated adults and to assess whether anti-viral immune responses are detectable in saliva (representative of the oral mucosa) as well as how these compare to circulating responses detectable in the blood. In a random subset of study participants they will offer a booster immunization and subsequently evaluate mucosal and circulating immune responses in the saliva, nasal washes (representative of the oral and respiratory mucosae) and blood 7 and 28 days and 1 year post-vaccination to determine whether additional predictive indicators for measles, mumps and/or rubella immunity can be identified.

Significantly, the proposed study has the potential to 1) Provide unique insights into similarities and differences between mucosal and circulating anti-viral immune responses to MMR vaccination as well as the duration of such responses; 2) Aid in the identification of a correlate of immune protection or novel indicator of responsiveness to mumps (and possibly measles and rubella) vaccination; and 3) Improve immune monitoring after MMR vaccination by using saliva and/or nasal washes to reduce invasiveness and provide a proof-of-concept for future studies.

Conditions
Mumps, Measles, Rubella
Being tested
MMR booster vaccination (as M-M-R-VaxPro)
Medical subject headings
Mumps, Measles, Rubella

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MMR booster vaccination (as M-M-R-VaxPro)Biological

    a single dose of MMR-containing vaccine (as M-M-R-VaxPro), in adults having previously received 2 lifetime doses of MMR-containing vaccine

Study groups in NCT05894395
Study groupRoleWhat they receive
MMR Booster Vaccination ArmExperimentalParticipants (adults 18+ having previously received 2 lifetime doses of MMR-containing vaccine) will receive a single MMR booster vaccination (3rd lifetime dose) as M-M-R-VaxPro.
Receives: Biological: MMR booster vaccination (as M-M-R-VaxPro)
Observational ArmNo interventionParticipants (adults 18+ having previously received 2 lifetime doses of MMR-containing vaccine) will be assessed at study enrollment and at a 1 year follow-up visit

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Immunogenicity post MMR-booster vaccination

    Immunogenicity will be assessed by evaluating anti-measles, -mumps, and -rubella serum Immunoglobulin G (IgG) titers post-booster vaccination. A 5-fold increase in titers for each virus between baseline (day 0) and day 28 post-booster vaccination will be considered "immunogenic".

    Measured: From admission to one year post vaccination

Secondary outcomes (4)
  1. Assessment of Immunoglobulin A (IgA) blood and mucosal immune responses to each virus (measles, mumps, and rubella)

    From screened participants, population-level IgA responses to measles, mumps, and rubella will be estimated. Virus-specific IgA responses in serum, saliva and nasal washes will be assessed at each timepoint by Enzyme-Linked Immunosorbent Assay (ELISA) and compared over time (day 0/ day 7/ day 28/ 1 year).

    Measured: From admission to one year post vaccination

  2. Assessment of Immunoglobulin G (IgG) blood and mucosal immune responses to each virus (measles, mumps, and rubella)

    From screened participants, population-level IgG responses to measles, mumps, and rubella will be estimated. Virus-specific IgG responses in serum, saliva and nasal washes will be assessed at each timepoint by Enzyme-Linked Fluorescent Assay (ELFA) and compared over time (day 0/ day 7/ day 28/ 1 year).

    Measured: From admission to one year post vaccination

  3. Assessment of virus-specific B cell blood and mucosal immune responses to each virus (measles, mumps, and rubella)

    From screened participants, population-level virus-specific B cell responses to measles, mumps, and rubella will be estimated. Virus-specific B cell responses in blood, saliva and nasal washes will be assessed at each timepoint by IgG Enzyme-Linked Immunosorbent Spot (ELISpot) assay and compared over time (day 0/ day 7/ day 28/ 1 year).

    Measured: From admission to one year post vaccination

  4. Assessment of virus-specific T cell blood and mucosal immune responses to each virus (measles, mumps, and rubella)

    From screened participants, population-level virus-specific T cell responses to measles, mumps, and rubella will be estimated. Virus-specific T cell responses in blood, saliva and nasal washes will be assessed at each timepoint by Interferon-gamma (IFN-gamma) ELISpot assay and compared over time (day 0/ day 7/ day 28/ 1 year).

    Measured: From admission to one year post vaccination

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jun 2023
  2. Study start1 Dec 2023
  3. Primary completion1 Mar 2025 (estimated)
  4. Study completion1 Sep 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants with two previous lifetime doses of MMR-containing vaccine will be randomized to receive a single M-M-R-VaxPro booster vaccination (3rd lifetime MMR-containing vaccine dose) or no intervention.
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05894395
Sponsor's protocol ID
MIPS101124
Acronym
MIPS
Status last verified
Jan 2024
First submitted
30 May 2023
Last updated
8 Jan 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing MMR booster vaccination (as M-M-R-VaxPro) in people with Mumps and Measles, run by University of Zurich at 2 sites in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Phung Lang, Ph.D. (+41 44 634 46 72, phung.lang@uzh.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Immunogenicity post MMR-booster vaccination (time frame: From admission to one year post vaccination). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in